Blockchain technology continues to evolve rapidly with scalability and efficiency as key challenges. Recursive SNARKs (Succinct Non-Interactive Arguments of Knowledge) have emerged as a breakthrough ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

At the moment, Infisical does not synchronize nested secret directories when setting up a sync integration (e.g. with Vault). This means that for the same connection, it is required to create a ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

axiom P : Nat → Prop axiom P.intro : P n inductive AckFuel : (n m : Nat) → Type where | step1 : AckFuel 0 m | step2 : AckFuel n 1 → AckFuel (n + 1) 0 | step3 : (∀ m', P m' → AckFuel n m') → AckFuel (n ...